ArticlePloS one2026
Prevalence and factors associated with treatment delay among colorectal cancer patients at Mulago National Referral Hospital and the Uganda Cancer Institute: A cross-sectional study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is an important cause of morbidity and mortality in Uganda. Timely treatment initiation is critical for outcomes, yet delays are common. This study assessed treatment delays and associated factors among CRC patients at Mulago National Referral Hospital (MNRH) and the Uganda Cancer Institute (UCI).
objectiveTo determine the diagnosis to treatment interval (DTI), prevalence of treatment delay, and the associated patient and clinicopathologic factors among CRC patients.
methodsA hospital-based cross-sectional study was conducted among 67 patients with histologically confirmed CRC between December 2024 and May 2025. Treatment delay was defined as >31 days between histological diagnosis and first oncologic treatment. Data were collected through interviews and record review. Descriptive statistics summarized demographics and clinical characteristics. Bivariate Poisson regression with robust variance estimation identified factors associated with delay; variables with p < 0.20 entered a multivariable model. Prevalence ratios (PRs) with 95% levels of confidence were reported. IRB approval was obtained (Ref: Mak-SOMREC-2024-1048).
resultsThe mean age was 50.5 years (SD: 15.1); 55.2% were female, and 71.6% (n = 48) had advanced-stage disease (Stage III/IV). The median DTI was 53 days (IQR: 25-95), with 70.1% (n = 47) experiencing delays. Median DTI by treatment: chemotherapy 53 days, radiotherapy 79 days, surgery 14 days. Socioeconomic vulnerability was the only factor independently associated with treatment delay. Patients with high socioeconomic vulnerability scores (≥4) had a 34% higher prevalence of delay (PR = 1.34, 95% CI: 1.01-1.78, p = 0.042).
conclusionMost CRC patients experienced treatment delays which were widespread and occurred across all categories; regardless of distance to the treatment facility, clinical status, or disease severity. Socioeconomic disadvantage was the only independent predictor, underscoring the role of structural and financial barriers in timely care. Targeted, context-specific interventions are urgently needed to reduce delays and improve outcomes.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.